93 results
8-K
EX-1.1
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
in conformity with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general … and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation
424B5
URGN
UroGen Pharma Ltd
18 Jun 24
Prospectus supplement for primary offering
5:05pm
and upper urinary tract where tumor visibility and access are challenging, and where there exists a significant amount of urine flow and voiding. We … shareholders may be exempt from shareholder approval under certain conditions.
Access to Corporate Records
Under the Israeli Companies Law
424B5
URGN
UroGen Pharma Ltd
17 Jun 24
Prospectus supplement for primary offering
4:19pm
visibility and access are challenging, and where there exists a significant amount of urine flow and voiding. We believe that these characteristics … approval of a company’s shareholders may be exempt from shareholder approval under certain conditions.
Access to Corporate Records
Under the Israeli
8-K
EX-99.1
URGN
UroGen Pharma Ltd
13 May 24
ENVISION data expected to support completion of UGN-102 NDA in Q3 2024
8:01am
download that may be needed to access the webcast.
UROGEN PHARMA LTD.
SELECTED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
(Unaudited
8-K
EX-99.1
vpomxg6 wicq
14 Mar 24
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
8:16am
8-K
EX-99.1
k4n3i
14 Nov 23
UroGen Pharma Reports Third Quarter 2023 Financial Results
12:00am
8-K
EX-99.1
oue9b6rh6
10 Aug 23
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
8:01am
8-K
EX-10.1
quq779e9 7cfdmsxg
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am
8-K
EX-99.1
9skor 4hxls7d
11 May 23
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
8:05am